MovDisordV3, PascalFrancis, Corpus, bibRecord, 000D32

A Longitudinal Program for Biomarker Development in Parkinson's Disease: A Feasibility Study

Identifieur interne : 000D32 ( PascalFrancis/Corpus ); précédent : 000D31; suivant : 000D33

A Longitudinal Program for Biomarker Development in Parkinson's Disease: A Feasibility Study

Auteurs : Bernard Ravina ; Caroline Tanner ; Diane Dieuliis ; Shirley Eberly ; Emily Flagg ; Wendy R. Galpern ; Stanley Fahn ; Christopher G. Goetz ; Stephen Grate ; Roger Kurlan ; Anthony E. Lang ; Kenneth Marek ; Karl Kieburtz ; David Oakes ; Robin Elliott ; Ira Shoulson

Source :

Movement disorders [ 0885-3185 ] ; 2009.

RBID : Pascal:09-0482382

Descripteurs français

Pascal (Inist)
- Maladie de Parkinson, Pathologie du système nerveux, Programme, Faisabilité.

English descriptors

KwdEn :
- Feasibility, Nervous system diseases, Parkinson disease, Program.

Abstract

Long-term follow up is necessary to understand the natural history of treated Parkinson's disease (PD). The Longitudinal and Biomarker Study in PD (LABS-PD) is an observational study designed to prospectively measure the evolution of motor and non-motor features of PD and sample promising biomarkers from early to late stage illness. LABS-PD is organized on the premise that cohorts from completed clinical trials can be re-recruited for long-term follow up. LABS-PD will eventually contain multiple cohorts, but to test the feasibility of the strategy, we examined enrollment and biomarker sampling in the initial cohorts. The first PD cohort (PostCEPT) comes from the de novo clinical trial of a mixed lineage kinase inhibitor (PRECEPT). We assessed the recruitment from PRECEPT to PostCEPT, the ability to link data from the two studies, and sample collection for a variety of biomarkers. A total of 537 of 709 eligible PRECEPT subjects (76%) enrolled in PostCEPT; 509 (95%) had repeat dopamine transporter imaging. PRECEPT clinical and imaging data were successfully linked to PostCEPT, to provide 3 to 4 year follow-up. A biomarker sub-study enrolled over 100 PD cases from PostCEPT and 100 controls to measure olfaction and blood markers of gene expression, α-synuclein, and proteomic profiles. We were also successful in linking clinical and biomarker data to DNA samples that have been collected in the publicly accessible Coriell repository. The PostCEPT cohort and associated studies strongly support the feasibility of the LABS-PD approach of retaining and repurposing clinical trial cohorts to collect longitudinal clinical and biomarker data.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 24`
A06				`@2 14`
A08	`01`	`1`	`ENG`	`@1 A Longitudinal Program for Biomarker Development in Parkinson's Disease: A Feasibility Study`
A11	`01`	`1`		`@1 RAVINA (Bernard)`
A11	`02`	`1`		`@1 TANNER (Caroline)`
A11	`03`	`1`		`@1 DIEULIIS (Diane)`
A11	`04`	`1`		`@1 EBERLY (Shirley)`
A11	`05`	`1`		`@1 FLAGG (Emily)`
A11	`06`	`1`		`@1 GALPERN (Wendy R.)`
A11	`07`	`1`		`@1 FAHN (Stanley)`
A11	`08`	`1`		`@1 GOETZ (Christopher G.)`
A11	`09`	`1`		`@1 GRATE (Stephen)`
A11	`10`	`1`		`@1 KURLAN (Roger)`
A11	`11`	`1`		`@1 LANG (Anthony E.)`
A11	`12`	`1`		`@1 MAREK (Kenneth)`
A11	`13`	`1`		`@1 KIEBURTZ (Karl)`
A11	`14`	`1`		`@1 OAKES (David)`
A11	`15`	`1`		`@1 ELLIOTT (Robin)`
A11	`16`	`1`		`@1 SHOULSON (Ira)`
A14	`01`			`@1 Department of Neurology, University of Rochester School of Medicine and Dentistry @2 Rochester, New York @3 USA @Z 1 aut. @Z 4 aut. @Z 5 aut. @Z 10 aut. @Z 13 aut. @Z 14 aut. @Z 16 aut.`
A14	`02`			`@1 The Parkinson's Institute @2 Sunnyvale, California @3 USA @Z 2 aut.`
A14	`03`			`@1 The National Institute of Neurological Disorders and Stroke (NINDS) @2 Bethesda, Maryland @3 USA @Z 3 aut. @Z 6 aut.`
A14	`04`			`@1 Department of Neurology, Columbia University @2 New York, New York @3 USA @Z 7 aut.`
A14	`05`			`@1 Department of Neurosciences, Rush University Medical Center @2 Chicago, Illinois @3 USA @Z 8 aut.`
A14	`06`			`@1 Telemedicine and Advanced Technology Research Center @2 Fort Detrick, Maryland @3 USA @Z 9 aut.`
A14	`07`			`@1 Department of Medicine, Division of Neurology, Univerisity of Toronto @2 Toronto, Ontario @3 CAN @Z 11 aut.`
A14	`08`			`@1 Institute for Neur-odegenerative Disorders @2 New Haven, Connecticut @3 USA @Z 12 aut.`
A14	`09`			`@1 The Parkinson's Disease Foundation @2 New York, New York @3 USA @Z 15 aut.`
A17	`01`	`1`		`@1 Parkinson Study Group LABS-PD Investigators @3 INC`
A20				`@1 2081-2090`
A21				`@1 2009`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000171427050070`
A44				`@0 0000 @1 © 2009 INIST-CNRS. All rights reserved.`
A45				`@0 39 ref.`
A47	`01`	`1`		`@0 09-0482382`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Long-term follow up is necessary to understand the natural history of treated Parkinson's disease (PD). The Longitudinal and Biomarker Study in PD (LABS-PD) is an observational study designed to prospectively measure the evolution of motor and non-motor features of PD and sample promising biomarkers from early to late stage illness. LABS-PD is organized on the premise that cohorts from completed clinical trials can be re-recruited for long-term follow up. LABS-PD will eventually contain multiple cohorts, but to test the feasibility of the strategy, we examined enrollment and biomarker sampling in the initial cohorts. The first PD cohort (PostCEPT) comes from the de novo clinical trial of a mixed lineage kinase inhibitor (PRECEPT). We assessed the recruitment from PRECEPT to PostCEPT, the ability to link data from the two studies, and sample collection for a variety of biomarkers. A total of 537 of 709 eligible PRECEPT subjects (76%) enrolled in PostCEPT; 509 (95%) had repeat dopamine transporter imaging. PRECEPT clinical and imaging data were successfully linked to PostCEPT, to provide 3 to 4 year follow-up. A biomarker sub-study enrolled over 100 PD cases from PostCEPT and 100 controls to measure olfaction and blood markers of gene expression, α-synuclein, and proteomic profiles. We were also successful in linking clinical and biomarker data to DNA samples that have been collected in the publicly accessible Coriell repository. The PostCEPT cohort and associated studies strongly support the feasibility of the LABS-PD approach of retaining and repurposing clinical trial cohorts to collect longitudinal clinical and biomarker data.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 02`
C03	`02`	`X`	`ENG`	`@0 Nervous system diseases @5 02`
C03	`02`	`X`	`SPA`	`@0 Sistema nervioso patología @5 02`
C03	`03`	`X`	`FRE`	`@0 Programme @5 09`
C03	`03`	`X`	`ENG`	`@0 Program @5 09`
C03	`03`	`X`	`SPA`	`@0 Programa @5 09`
C03	`04`	`X`	`FRE`	`@0 Faisabilité @5 10`
C03	`04`	`X`	`ENG`	`@0 Feasibility @5 10`
C03	`04`	`X`	`SPA`	`@0 Practicabilidad @5 10`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
N21				`@1 348`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 09-0482382 INIST
ET :	A Longitudinal Program for Biomarker Development in Parkinson's Disease: A Feasibility Study
AU :	RAVINA (Bernard); TANNER (Caroline); DIEULIIS (Diane); EBERLY (Shirley); FLAGG (Emily); GALPERN (Wendy R.); FAHN (Stanley); GOETZ (Christopher G.); GRATE (Stephen); KURLAN (Roger); LANG (Anthony E.); MAREK (Kenneth); KIEBURTZ (Karl); OAKES (David); ELLIOTT (Robin); SHOULSON (Ira)
AF :	Department of Neurology, University of Rochester School of Medicine and Dentistry/Rochester, New York/Etats-Unis (1 aut., 4 aut., 5 aut., 10 aut., 13 aut., 14 aut., 16 aut.); The Parkinson's Institute/Sunnyvale, California/Etats-Unis (2 aut.); The National Institute of Neurological Disorders and Stroke (NINDS)/Bethesda, Maryland/Etats-Unis (3 aut., 6 aut.); Department of Neurology, Columbia University/New York, New York/Etats-Unis (7 aut.); Department of Neurosciences, Rush University Medical Center/Chicago, Illinois/Etats-Unis (8 aut.); Telemedicine and Advanced Technology Research Center/Fort Detrick, Maryland/Etats-Unis (9 aut.); Department of Medicine, Division of Neurology, Univerisity of Toronto/Toronto, Ontario/Canada (11 aut.); Institute for Neur-odegenerative Disorders/New Haven, Connecticut/Etats-Unis (12 aut.); The Parkinson's Disease Foundation/New York, New York/Etats-Unis (15 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2009; Vol. 24; No. 14; Pp. 2081-2090; Bibl. 39 ref.
LA :	Anglais
EA :	Long-term follow up is necessary to understand the natural history of treated Parkinson's disease (PD). The Longitudinal and Biomarker Study in PD (LABS-PD) is an observational study designed to prospectively measure the evolution of motor and non-motor features of PD and sample promising biomarkers from early to late stage illness. LABS-PD is organized on the premise that cohorts from completed clinical trials can be re-recruited for long-term follow up. LABS-PD will eventually contain multiple cohorts, but to test the feasibility of the strategy, we examined enrollment and biomarker sampling in the initial cohorts. The first PD cohort (PostCEPT) comes from the de novo clinical trial of a mixed lineage kinase inhibitor (PRECEPT). We assessed the recruitment from PRECEPT to PostCEPT, the ability to link data from the two studies, and sample collection for a variety of biomarkers. A total of 537 of 709 eligible PRECEPT subjects (76%) enrolled in PostCEPT; 509 (95%) had repeat dopamine transporter imaging. PRECEPT clinical and imaging data were successfully linked to PostCEPT, to provide 3 to 4 year follow-up. A biomarker sub-study enrolled over 100 PD cases from PostCEPT and 100 controls to measure olfaction and blood markers of gene expression, α-synuclein, and proteomic profiles. We were also successful in linking clinical and biomarker data to DNA samples that have been collected in the publicly accessible Coriell repository. The PostCEPT cohort and associated studies strongly support the feasibility of the LABS-PD approach of retaining and repurposing clinical trial cohorts to collect longitudinal clinical and biomarker data.
CC :	002B17; 002B17G
FD :	Maladie de Parkinson; Pathologie du système nerveux; Programme; Faisabilité
FG :	Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central
ED :	Parkinson disease; Nervous system diseases; Program; Feasibility
EG :	Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease
SD :	Parkinson enfermedad; Sistema nervioso patología; Programa; Practicabilidad
LO :	INIST-20953.354000171427050070
ID :	09-0482382

Links to Exploration step

Pascal:09-0482382

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">A Longitudinal Program for Biomarker Development in Parkinson's Disease: A Feasibility Study</title>
<author><name sortKey="Ravina, Bernard" sort="Ravina, Bernard" uniqKey="Ravina B" first="Bernard" last="Ravina">Bernard Ravina</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tanner, Caroline" sort="Tanner, Caroline" uniqKey="Tanner C" first="Caroline" last="Tanner">Caroline Tanner</name>
<affiliation><inist:fA14 i1="02"><s1>The Parkinson's Institute</s1>
<s2>Sunnyvale, California</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dieuliis, Diane" sort="Dieuliis, Diane" uniqKey="Dieuliis D" first="Diane" last="Dieuliis">Diane Dieuliis</name>
<affiliation><inist:fA14 i1="03"><s1>The National Institute of Neurological Disorders and Stroke (NINDS)</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Eberly, Shirley" sort="Eberly, Shirley" uniqKey="Eberly S" first="Shirley" last="Eberly">Shirley Eberly</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Flagg, Emily" sort="Flagg, Emily" uniqKey="Flagg E" first="Emily" last="Flagg">Emily Flagg</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Galpern, Wendy R" sort="Galpern, Wendy R" uniqKey="Galpern W" first="Wendy R." last="Galpern">Wendy R. Galpern</name>
<affiliation><inist:fA14 i1="03"><s1>The National Institute of Neurological Disorders and Stroke (NINDS)</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fahn, Stanley" sort="Fahn, Stanley" uniqKey="Fahn S" first="Stanley" last="Fahn">Stanley Fahn</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurology, Columbia University</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Neurosciences, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Grate, Stephen" sort="Grate, Stephen" uniqKey="Grate S" first="Stephen" last="Grate">Stephen Grate</name>
<affiliation><inist:fA14 i1="06"><s1>Telemedicine and Advanced Technology Research Center</s1>
<s2>Fort Detrick, Maryland</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kurlan, Roger" sort="Kurlan, Roger" uniqKey="Kurlan R" first="Roger" last="Kurlan">Roger Kurlan</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Medicine, Division of Neurology, Univerisity of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Marek, Kenneth" sort="Marek, Kenneth" uniqKey="Marek K" first="Kenneth" last="Marek">Kenneth Marek</name>
<affiliation><inist:fA14 i1="08"><s1>Institute for Neur-odegenerative Disorders</s1>
<s2>New Haven, Connecticut</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Oakes, David" sort="Oakes, David" uniqKey="Oakes D" first="David" last="Oakes">David Oakes</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Elliott, Robin" sort="Elliott, Robin" uniqKey="Elliott R" first="Robin" last="Elliott">Robin Elliott</name>
<affiliation><inist:fA14 i1="09"><s1>The Parkinson's Disease Foundation</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Shoulson, Ira" sort="Shoulson, Ira" uniqKey="Shoulson I" first="Ira" last="Shoulson">Ira Shoulson</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">09-0482382</idno>
<date when="2009">2009</date>
<idno type="stanalyst">PASCAL 09-0482382 INIST</idno>
<idno type="RBID">Pascal:09-0482382</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000D32</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">A Longitudinal Program for Biomarker Development in Parkinson's Disease: A Feasibility Study</title>
<author><name sortKey="Ravina, Bernard" sort="Ravina, Bernard" uniqKey="Ravina B" first="Bernard" last="Ravina">Bernard Ravina</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tanner, Caroline" sort="Tanner, Caroline" uniqKey="Tanner C" first="Caroline" last="Tanner">Caroline Tanner</name>
<affiliation><inist:fA14 i1="02"><s1>The Parkinson's Institute</s1>
<s2>Sunnyvale, California</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dieuliis, Diane" sort="Dieuliis, Diane" uniqKey="Dieuliis D" first="Diane" last="Dieuliis">Diane Dieuliis</name>
<affiliation><inist:fA14 i1="03"><s1>The National Institute of Neurological Disorders and Stroke (NINDS)</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Eberly, Shirley" sort="Eberly, Shirley" uniqKey="Eberly S" first="Shirley" last="Eberly">Shirley Eberly</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Flagg, Emily" sort="Flagg, Emily" uniqKey="Flagg E" first="Emily" last="Flagg">Emily Flagg</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Galpern, Wendy R" sort="Galpern, Wendy R" uniqKey="Galpern W" first="Wendy R." last="Galpern">Wendy R. Galpern</name>
<affiliation><inist:fA14 i1="03"><s1>The National Institute of Neurological Disorders and Stroke (NINDS)</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fahn, Stanley" sort="Fahn, Stanley" uniqKey="Fahn S" first="Stanley" last="Fahn">Stanley Fahn</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurology, Columbia University</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Neurosciences, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Grate, Stephen" sort="Grate, Stephen" uniqKey="Grate S" first="Stephen" last="Grate">Stephen Grate</name>
<affiliation><inist:fA14 i1="06"><s1>Telemedicine and Advanced Technology Research Center</s1>
<s2>Fort Detrick, Maryland</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kurlan, Roger" sort="Kurlan, Roger" uniqKey="Kurlan R" first="Roger" last="Kurlan">Roger Kurlan</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Medicine, Division of Neurology, Univerisity of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Marek, Kenneth" sort="Marek, Kenneth" uniqKey="Marek K" first="Kenneth" last="Marek">Kenneth Marek</name>
<affiliation><inist:fA14 i1="08"><s1>Institute for Neur-odegenerative Disorders</s1>
<s2>New Haven, Connecticut</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Oakes, David" sort="Oakes, David" uniqKey="Oakes D" first="David" last="Oakes">David Oakes</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Elliott, Robin" sort="Elliott, Robin" uniqKey="Elliott R" first="Robin" last="Elliott">Robin Elliott</name>
<affiliation><inist:fA14 i1="09"><s1>The Parkinson's Disease Foundation</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Shoulson, Ira" sort="Shoulson, Ira" uniqKey="Shoulson I" first="Ira" last="Shoulson">Ira Shoulson</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Feasibility</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Program</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>Programme</term>
<term>Faisabilité</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Long-term follow up is necessary to understand the natural history of treated Parkinson's disease (PD). The Longitudinal and Biomarker Study in PD (LABS-PD) is an observational study designed to prospectively measure the evolution of motor and non-motor features of PD and sample promising biomarkers from early to late stage illness. LABS-PD is organized on the premise that cohorts from completed clinical trials can be re-recruited for long-term follow up. LABS-PD will eventually contain multiple cohorts, but to test the feasibility of the strategy, we examined enrollment and biomarker sampling in the initial cohorts. The first PD cohort (PostCEPT) comes from the de novo clinical trial of a mixed lineage kinase inhibitor (PRECEPT). We assessed the recruitment from PRECEPT to PostCEPT, the ability to link data from the two studies, and sample collection for a variety of biomarkers. A total of 537 of 709 eligible PRECEPT subjects (76%) enrolled in PostCEPT; 509 (95%) had repeat dopamine transporter imaging. PRECEPT clinical and imaging data were successfully linked to PostCEPT, to provide 3 to 4 year follow-up. A biomarker sub-study enrolled over 100 PD cases from PostCEPT and 100 controls to measure olfaction and blood markers of gene expression, α-synuclein, and proteomic profiles. We were also successful in linking clinical and biomarker data to DNA samples that have been collected in the publicly accessible Coriell repository. The PostCEPT cohort and associated studies strongly support the feasibility of the LABS-PD approach of retaining and repurposing clinical trial cohorts to collect longitudinal clinical and biomarker data.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>24</s2>
</fA05>
<fA06><s2>14</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>A Longitudinal Program for Biomarker Development in Parkinson's Disease: A Feasibility Study</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>RAVINA (Bernard)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>TANNER (Caroline)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>DIEULIIS (Diane)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>EBERLY (Shirley)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>FLAGG (Emily)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>GALPERN (Wendy R.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>FAHN (Stanley)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>GOETZ (Christopher G.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>GRATE (Stephen)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>KURLAN (Roger)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>LANG (Anthony E.)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>MAREK (Kenneth)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>KIEBURTZ (Karl)</s1>
</fA11>
<fA11 i1="14" i2="1"><s1>OAKES (David)</s1>
</fA11>
<fA11 i1="15" i2="1"><s1>ELLIOTT (Robin)</s1>
</fA11>
<fA11 i1="16" i2="1"><s1>SHOULSON (Ira)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>16 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>The Parkinson's Institute</s1>
<s2>Sunnyvale, California</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>The National Institute of Neurological Disorders and Stroke (NINDS)</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Neurology, Columbia University</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Neurosciences, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Telemedicine and Advanced Technology Research Center</s1>
<s2>Fort Detrick, Maryland</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Department of Medicine, Division of Neurology, Univerisity of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Institute for Neur-odegenerative Disorders</s1>
<s2>New Haven, Connecticut</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>The Parkinson's Disease Foundation</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>15 aut.</sZ>
</fA14>
<fA17 i1="01" i2="1"><s1>Parkinson Study Group LABS-PD Investigators</s1>
<s3>INC</s3>
</fA17>
<fA20><s1>2081-2090</s1>
</fA20>
<fA21><s1>2009</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000171427050070</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2009 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>39 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>09-0482382</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Long-term follow up is necessary to understand the natural history of treated Parkinson's disease (PD). The Longitudinal and Biomarker Study in PD (LABS-PD) is an observational study designed to prospectively measure the evolution of motor and non-motor features of PD and sample promising biomarkers from early to late stage illness. LABS-PD is organized on the premise that cohorts from completed clinical trials can be re-recruited for long-term follow up. LABS-PD will eventually contain multiple cohorts, but to test the feasibility of the strategy, we examined enrollment and biomarker sampling in the initial cohorts. The first PD cohort (PostCEPT) comes from the de novo clinical trial of a mixed lineage kinase inhibitor (PRECEPT). We assessed the recruitment from PRECEPT to PostCEPT, the ability to link data from the two studies, and sample collection for a variety of biomarkers. A total of 537 of 709 eligible PRECEPT subjects (76%) enrolled in PostCEPT; 509 (95%) had repeat dopamine transporter imaging. PRECEPT clinical and imaging data were successfully linked to PostCEPT, to provide 3 to 4 year follow-up. A biomarker sub-study enrolled over 100 PD cases from PostCEPT and 100 controls to measure olfaction and blood markers of gene expression, α-synuclein, and proteomic profiles. We were also successful in linking clinical and biomarker data to DNA samples that have been collected in the publicly accessible Coriell repository. The PostCEPT cohort and associated studies strongly support the feasibility of the LABS-PD approach of retaining and repurposing clinical trial cohorts to collect longitudinal clinical and biomarker data.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Programme</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Program</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Programa</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Faisabilité</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Feasibility</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Practicabilidad</s0>
<s5>10</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>348</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 09-0482382 INIST</NO>
<ET>A Longitudinal Program for Biomarker Development in Parkinson's Disease: A Feasibility Study</ET>
<AU>RAVINA (Bernard); TANNER (Caroline); DIEULIIS (Diane); EBERLY (Shirley); FLAGG (Emily); GALPERN (Wendy R.); FAHN (Stanley); GOETZ (Christopher G.); GRATE (Stephen); KURLAN (Roger); LANG (Anthony E.); MAREK (Kenneth); KIEBURTZ (Karl); OAKES (David); ELLIOTT (Robin); SHOULSON (Ira)</AU>
<AF>Department of Neurology, University of Rochester School of Medicine and Dentistry/Rochester, New York/Etats-Unis (1 aut., 4 aut., 5 aut., 10 aut., 13 aut., 14 aut., 16 aut.); The Parkinson's Institute/Sunnyvale, California/Etats-Unis (2 aut.); The National Institute of Neurological Disorders and Stroke (NINDS)/Bethesda, Maryland/Etats-Unis (3 aut., 6 aut.); Department of Neurology, Columbia University/New York, New York/Etats-Unis (7 aut.); Department of Neurosciences, Rush University Medical Center/Chicago, Illinois/Etats-Unis (8 aut.); Telemedicine and Advanced Technology Research Center/Fort Detrick, Maryland/Etats-Unis (9 aut.); Department of Medicine, Division of Neurology, Univerisity of Toronto/Toronto, Ontario/Canada (11 aut.); Institute for Neur-odegenerative Disorders/New Haven, Connecticut/Etats-Unis (12 aut.); The Parkinson's Disease Foundation/New York, New York/Etats-Unis (15 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2009; Vol. 24; No. 14; Pp. 2081-2090; Bibl. 39 ref.</SO>
<LA>Anglais</LA>
<EA>Long-term follow up is necessary to understand the natural history of treated Parkinson's disease (PD). The Longitudinal and Biomarker Study in PD (LABS-PD) is an observational study designed to prospectively measure the evolution of motor and non-motor features of PD and sample promising biomarkers from early to late stage illness. LABS-PD is organized on the premise that cohorts from completed clinical trials can be re-recruited for long-term follow up. LABS-PD will eventually contain multiple cohorts, but to test the feasibility of the strategy, we examined enrollment and biomarker sampling in the initial cohorts. The first PD cohort (PostCEPT) comes from the de novo clinical trial of a mixed lineage kinase inhibitor (PRECEPT). We assessed the recruitment from PRECEPT to PostCEPT, the ability to link data from the two studies, and sample collection for a variety of biomarkers. A total of 537 of 709 eligible PRECEPT subjects (76%) enrolled in PostCEPT; 509 (95%) had repeat dopamine transporter imaging. PRECEPT clinical and imaging data were successfully linked to PostCEPT, to provide 3 to 4 year follow-up. A biomarker sub-study enrolled over 100 PD cases from PostCEPT and 100 controls to measure olfaction and blood markers of gene expression, α-synuclein, and proteomic profiles. We were also successful in linking clinical and biomarker data to DNA samples that have been collected in the publicly accessible Coriell repository. The PostCEPT cohort and associated studies strongly support the feasibility of the LABS-PD approach of retaining and repurposing clinical trial cohorts to collect longitudinal clinical and biomarker data.</EA>
<CC>002B17; 002B17G</CC>
<FD>Maladie de Parkinson; Pathologie du   système nerveux; Programme; Faisabilité</FD>
<FG>Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du   système nerveux central</FG>
<ED>Parkinson disease; Nervous system diseases; Program; Feasibility</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease</EG>
<SD>Parkinson enfermedad; Sistema nervioso patología; Programa; Practicabilidad</SD>
<LO>INIST-20953.354000171427050070</LO>
<ID>09-0482382</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D32 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000D32 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:09-0482382
   |texte=   A Longitudinal Program for Biomarker Development in Parkinson's Disease: A Feasibility Study
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

A Longitudinal Program for Biomarker Development in Parkinson's Disease: A Feasibility Study

A Longitudinal Program for Biomarker Development in Parkinson's Disease: A Feasibility Study

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri